Hildenbrand R - Search Results

1

Validation of immunolocalization of the urokinase receptor expression in ductal carcinoma in situ of the breast: comparison with detection by non-isotopic in-situ hybridization.

Hildenbrand R, Leitz M, Magdolen V, Luther T, Albrecht S, Graeff H, Stutte HJ, Bleyl U, Schmitt M. Hildenbrand R, et al. Histopathology. 2000 Jun;36(6):499-504. doi: 10.1046/j.1365-2559.2000.00899.x. Histopathology. 2000. PMID: 10849091

2

Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry.

Hildenbrand R, Glienke W, Magdolen V, Graeff H, Stutte HJ, Schmitt M. Hildenbrand R, et al. Histochem Cell Biol. 1998 Jul;110(1):27-32. doi: 10.1007/s004180050261. Histochem Cell Biol. 1998. PMID: 9681686

3

Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue.

Hildenbrand R, Wolf G, Böhme B, Bleyl U, Steinborn A. Hildenbrand R, et al. J Leukoc Biol. 1999 Jul;66(1):40-9. doi: 10.1002/jlb.66.1.40. J Leukoc Biol. 1999. PMID: 10410988

4

In vitro suppression of urokinase plasminogen activator in breast cancer cells--a comparison of two antisense strategies.

Arens N, Gandhari M, Bleyl U, Hildenbrand R. Arens N, et al. Among authors: hildenbrand r. Int J Oncol. 2005 Jan;26(1):113-9. Int J Oncol. 2005. PMID: 15586231

5

Urokinase plasminogen activator induces angiogenesis and tumor vessel invasion in breast cancer.

Hildenbrand R, Dilger I, Hörlin A, Stutte HJ. Hildenbrand R, et al. Pathol Res Pract. 1995 Jun;191(5):403-9. doi: 10.1016/S0344-0338(11)80726-0. Pathol Res Pract. 1995. PMID: 7479358

6

Urokinase and macrophages in tumour angiogenesis.

Hildenbrand R, Dilger I, Hörlin A, Stutte HJ. Hildenbrand R, et al. Br J Cancer. 1995 Oct;72(4):818-23. doi: 10.1038/bjc.1995.419. Br J Cancer. 1995. PMID: 7547226 Free PMC article.

7

Transforming growth factor-beta stimulates urokinase expression in tumor-associated macrophages of the breast.

Hildenbrand R, Jansen C, Wolf G, Böhme B, Berger S, von Minckwitz G, Hörlin A, Kaufmann M, Stutte HJ. Hildenbrand R, et al. Lab Invest. 1998 Jan;78(1):59-71. Lab Invest. 1998. PMID: 9461122

8

Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer.

Wolf G, Hildenbrand R, Schwar C, Grobholz R, Kaufmann M, Stutte HJ, Strebhardt K, Bleyl U. Wolf G, et al. Among authors: hildenbrand r. Pathol Res Pract. 2000;196(11):753-9. doi: 10.1016/S0344-0338(00)80107-7. Pathol Res Pract. 2000. PMID: 11186170

9

c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical significance.

Schleger C, Verbeke C, Hildenbrand R, Zentgraf H, Bleyl U. Schleger C, et al. Among authors: hildenbrand r. Mod Pathol. 2002 Apr;15(4):462-9. doi: 10.1038/modpathol.3880547. Mod Pathol. 2002. PMID: 11950922

10

HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer.

Arens N, Bleyl U, Hildenbrand R. Arens N, et al. Among authors: hildenbrand r. Virchows Arch. 2005 May;446(5):489-96. doi: 10.1007/s00428-005-1244-0. Epub 2005 Apr 19. Virchows Arch. 2005. PMID: 15838646

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

67 results

Search Page

Filters